Published in:
Open Access
01-09-2018 | Review
Identifying cisplatin-induced kidney damage in paediatric oncology patients
Authors:
Chris D. Barton, Barry Pizer, Caroline Jones, Louise Oni, Munir Pirmohamed, Daniel B. Hawcutt
Published in:
Pediatric Nephrology
|
Issue 9/2018
Login to get access
Abstract
Cisplatin is one chemotherapeutic agent used to treat childhood cancer in numerous treatment protocols, including as a single agent. It is likely to remain in clinical use over the long term. However, cisplatin-related toxicities, including neurotoxicity and nephrotoxicity, are common, affecting treatment, day-to-day life and survival of such children. With one in 700 young adults having survived childhood cancer, patients who have completed chemotherapy that includes cisplatin can experience long-term morbidity due to treatment-related adverse reactions. A better understanding of these toxicities is essential to facilitate prevention, surveillance and management. This review article discusses the effect of cisplatin-induced nephrotoxicity (Cis-N) in children and considers the underlying mechanisms. We focus on clinical features and identification of Cis-N (e.g. investigations and biomarkers) and the importance of magnesium homeostasis and supplementation.